Rohner et al, 2007. Differentiation-promoting drugs up-regulate NKG2D ligand expression and enhance the susceptibility of acute myeloid leukemia cells to natural killer cell-mediated lysis Leuk Res.

Tang et al, 2008. Induction of MHC class I-related chain B (MICB) by 5-aza-2'-deoxycytidine Biochem Biophys Res Commun.

Romagné et al, 2009. Preclinical characterization of 1-7F9, a novel human anti-KIR receptor therapeutic antibody that augments natural killer-mediated killing of tumor cells Blood

Liu et al, 2009. DNA methylation inhibition increases T cell KIR expression through effects on both promoter methylation and transcription factors Clin Immunol.

Gao et al, 2009. Demethylating treatment suppresses natural killer cell cytolytic activity Mol Immunol.

Schmiedel et al, 2011. Azacytidine impairs NK cell reactivity while decitabine augments NK cell responsiveness toward stimulation Int J Cancer

Vey et al, 2012. A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission Blood

Kohrt et al, 2014. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies Blood

Nijhof et al, 2015. Daratumumab mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti KIR IPH2102 and lenalidomide Haematologica

Sohlberg et al, 2015. Imprint of 5-azacytidine on the natural killer cell repertoire during systemic treatment for high-risk myelodysplastic syndrome Oncotarget

Subscribe to Lirilumab